PRTK — Paratek Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $127.83m
- $343.47m
- $160.27m
U.S. STOCKS ON THE MOVE-Conagra, Rite Aid, Match Group, Apogee,
U.S. STOCKS ON THE MOVE-Rite Aid, Conagra, Apogee, Micron
U.S. STOCKS ON THE MOVE-Match Group, Conagra, Micron, Paratek Pharma
Paratek Pharma jumps on BARDA award for antibiotic
NASDAQ RESUMED AT 05:40 PM
Brief: Paratek Awarded Barda Project Bioshield Contract For Nuzyra
NASDAQ TRADE HALT HALT NEWS PENDING AT 05:00 PM
Brief: Paratek Pharmaceuticals Reports Third Quarter Results
U.S. STOCKS ON THE MOVE-Uber, Netflix, AbbVie, Colgate-Palmolive
U.S. STOCKS ON THE MOVE-Exxon Mobil, Colgate-Palmolive, Pinterest, Fitbit
Paratek Pharma: Hits record low as UTI drug fails to impress in study
Brief: Paratek Announces Top Line Results Of Phase 2 Clinical Studies Of Omadacycline In UTI
Brief: Paratek Withdraws European Marketing Authorization Application For Oral And Intravenous NUZYRA In Skin Infections & Pneumonia
Brief: Paratek Pharma Presenting New Data From Nuzyra Development Program At Idweek 2019
U.S. STOCKS ON THE MOVE-Campbell Soup, Tesla, Dell, Ambarella
U.S. STOCKS ON THE MOVE-Tesla, Dell, Campbell Soup, Alexion
Paratek rises on positive data for antibiotic for skin infections
Brief: Paratek Pharma - The Lancet Infectious Diseases Publishes Results From Paratek’S Phase 3 Oral Only Dosing Study Of Nuzyra (Omadacycline) For Skin Infections
U.S. STOCKS ON THE MOVE-Walt Disney, CVS Health Corp, Allakos